Cancer begins in your cells, which are the building blocks of your body. Normally, your body forms new cells as you need them, replacing old cells that die. Sometimes this process goes wrong. New cells grow even when you don't need them, and old cells don't die when they should. These extra cells can form a mass called a tumor. Tumors can be benign or malignant. Benign tumors aren't cancer while malignant ones are. Cells from malignant tumors can invade nearby tissues. They can also break away and spread to other parts of the body.
University of Wisconsin-Madison researchers have developed a safer and more efficient way to deliver a promising new method for treating cancer and liver disorders and for vaccination -- including a COVID-19 vaccine from Moderna Therapeutics that has advanced to clinical trials with humans.
Cancer cases have been rising over the years and according to the statistics, the number of people living with cancer will continue to increase.
Scientists at Hokkaido University and collaborators have identified how inflammatory changes in tumors caused by chemotherapy trigger blood vessel anomalies and thus drug-resistance, resulting in the poor prognosis of cancer patients.
While scientists still don't fully understand the diverse nature of RNA molecules, it is believed that the proteins binding to them, called RNA-binding proteins, are associated with many disease formation.
In the field of molecular biology, chaperones are a group of proteins that help regulate protein folding. Folding is a significant step in protein synthesis.
A method known as CAR-T therapy has been used successfully in patients with blood cancers such as lymphoma and leukemia.
Researchers have discovered that a living cell’s system meant for avoiding genetic damage can fail so much that it would be better off without it.
Cancers arise when the genetic code of normal cells is altered, causing excessive growth. Researchers from the Cancer Science Institute of Singapore at the National University of Singapore have discovered a protein that drives the growth of cancers of the esophagus or liver by altering the genetic code in a novel way.
Sanford Burnham Prebys Medical Discovery Institute today announced a research agreement with Eli Lilly and Company (Lilly) to characterize Lilly's next-generation anti-SARS-CoV-2 antibodies.
Ion channels and membrane transporters are in the business of moving ions and small molecules across cellular membranes. They are essential for metabolic and cellular homeostasis, and for a host of biological signaling pathways.
By sequencing entire genomes for DNA modifications, and analyzing both cancer tissues and healthy ones, Hackensack Meridian Health researchers and doctors have found what could be a key to risks for cancer and other diseases: specific locations in the DNA where those expression changes (methylation) are imbalanced, according to a new publication.
Scientists from Rensselaer Polytechnic Institute have designed and developed chemically engineered peptides that may prove useful to fight some of the most prevalent human health challenges.
Genomic mutation testing is critical to the therapeutic selection and management of patients with colorectal cancer.
An MRI scan used for heart disease could help assess whether children's cancers are especially aggressive and spot early signs that treatments are working.
When neurons fire an electrical impulse, they also experience a surge of calcium ions.
The concept that cancer development is “monitored and prevented” by the immune system was first suggested at the beginning of the previous century.
In the past, the potential to sequence the genome of the tumor has redefined the treatment of cancer by detecting cancer drivers at the molecular level.
Phytoalexins have attracted a great deal of interest because of their major role in plant health and their health-promoting effects in humans.
The ability to sequence the genome of a tumor has revolutionized cancer treatment over the years by identifying drivers of cancer at the molecular level.
Scientists from the Immanuel Kant Baltic Federal University and National University of Science and Technology "MISiS" have studied how magnet nanoparticles affect cancer cells in the human liver.